These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 9224631)
1. Internalization and down-regulation of the prostacyclin receptor in human platelets. Giovanazzi S; Accomazzo MR; Letari O; Oliva D; Nicosia S Biochem J; 1997 Jul; 325 ( Pt 1)(Pt 1):71-7. PubMed ID: 9224631 [TBL] [Abstract][Full Text] [Related]
2. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors. Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350 [TBL] [Abstract][Full Text] [Related]
3. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526 [TBL] [Abstract][Full Text] [Related]
4. The use of a prostacyclin analogue, [3H]iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cells. Hall JM; Strange PG Biosci Rep; 1984 Nov; 4(11):941-8. PubMed ID: 6084527 [TBL] [Abstract][Full Text] [Related]
6. Prostacyclin receptor desensitization is a reversible phenomenon in human platelets. Fisch A; Tobusch K; Veit K; Meyer J; Darius H Circulation; 1997 Aug; 96(3):756-60. PubMed ID: 9264479 [TBL] [Abstract][Full Text] [Related]
7. TEI-9063, a stable and highly specific prostacyclin analogue for the prostacyclin receptor in mastocytoma P-815 cells. Negishi M; Hashimoto H; Yatsunami K; Kurozumi S; Ichikawa A Prostaglandins; 1991 Sep; 42(3):225-37. PubMed ID: 1723528 [TBL] [Abstract][Full Text] [Related]
8. Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. Jaschonek K; Faul C; Schmidt H; Renn W Eur J Pharmacol; 1988 Mar; 147(2):187-96. PubMed ID: 2452749 [TBL] [Abstract][Full Text] [Related]
9. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin. Jaschonek K; Faul C; Daiss W; Weisenberger H Prostaglandins Leukot Med; 1986 Oct; 24(2-3):199-206. PubMed ID: 2432618 [TBL] [Abstract][Full Text] [Related]
10. Investigation of selective [3H]iloprost binding sites on human platelet membranes. Steurer G; Jankovic B; Ettl K; Schernthaner G Prog Clin Biol Res; 1987; 242():25-34. PubMed ID: 2444987 [No Abstract] [Full Text] [Related]
11. The use of stable prostaglandins to investigate prostacyclin (PGI2)-binding sites and PGI2-sensitive adenylate cyclase in human platelet membranes. Lombroso M; Nicosia S; Paoletti R; Whittle BJ; Moncada S; Vane JR Prostaglandins; 1984 Feb; 27(2):321-33. PubMed ID: 6326201 [TBL] [Abstract][Full Text] [Related]
12. The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells. Wilkins AJ; MacDermot J Eur J Pharmacol; 1986 Aug; 127(1-2):117-9. PubMed ID: 2428638 [TBL] [Abstract][Full Text] [Related]
13. Concurrent down-regulation of IP prostanoid receptors and the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs) during prolonged exposure of neuroblastoma x glioma cells to prostanoid agonists. Quantification and functional implications. Adie EJ; Mullaney I; McKenzie FR; Milligan G Biochem J; 1992 Jul; 285 ( Pt 2)(Pt 2):529-36. PubMed ID: 1379045 [TBL] [Abstract][Full Text] [Related]
14. Identification of the prostacyclin receptor by radiation inactivation. Leigh PJ; Cramp WA; MacDermot J J Biol Chem; 1984 Oct; 259(20):12431-6. PubMed ID: 6208187 [TBL] [Abstract][Full Text] [Related]
15. Interaction between platelet receptor and iloprost isomers. Tsai AL; Vijjeswarapu H; Wu KK Biochim Biophys Acta; 1988 Jul; 942(2):220-6. PubMed ID: 2456096 [TBL] [Abstract][Full Text] [Related]
16. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Seiler SM; Brassard CL; Federici ME; Romine J; Meanwell NA Prostaglandins; 1997 Jan; 53(1):21-35. PubMed ID: 9068064 [TBL] [Abstract][Full Text] [Related]
17. Diminished inhibition of adhesion molecule expression in prostacyclin receptor desensitized human platelets. Darius H; Veit K; Binz C; Fisch A; Meyer J Agents Actions Suppl; 1995; 45():77-83. PubMed ID: 7536385 [TBL] [Abstract][Full Text] [Related]
18. Prostacyclin receptor expression on platelets of humans with type 2 diabetes is inversely correlated with hemoglobin A1c levels. Knebel SM; Sprague RS; Stephenson AH Prostaglandins Other Lipid Mediat; 2015; 116-117():131-5. PubMed ID: 25617843 [TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic. Meanwell NA; Rosenfeld MJ; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Seiler SM J Med Chem; 1992 Jan; 35(2):389-97. PubMed ID: 1370696 [TBL] [Abstract][Full Text] [Related]
20. Epoprostenol (prostacyclin, PGI2) binding and activation of adenylate cyclase in platelets of diabetic and control subjects. Shepherd GL; Lewis PJ; Blair IA; de Mey C; MacDermot J Br J Clin Pharmacol; 1983 Jan; 15(1):77-81. PubMed ID: 6342639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]